Business
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2
About this update from Oculis Holding Ag
[{"type":"text","content":"ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySebastian Wolf, M.D., Ph.D. appointed as Chief Medical Advisor, Ophthalmology, following the material advancement in retina programs with recent enrollment completion of Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema and positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the appointments of Mark Kupersmith, M.D. as Chief Medical Advisor, Neuro-Ophthalmology and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisor, Ophthalmology. Over the past year, Oculis has achieved significant progress across its innovative and differentiated pipeline. The company completed enrollment in both Phase 3 DIAMOND trials with OCS-01 in diabetic macular edema. It also aligned with the U.S. FDA on the first-ever genotype-based development program in ophthalmology with Licaminlimab (OCS-02) to drive precision medicine in dry eye disease. In addition, Oculis announced positive topline results for Privosegtor (OCS-05) in acute optic neuritis, a pivotal step towards unlocking a new era of potential therapies targeting neuronal and axonal preservation and addressing a long-standing gap in neuro-protection. Mark Kupersmith, M.D., as Chief Medical Advisor, Neuro-Ophthalmology, brings in depth scientific expertise in both ophthalmology and neurology and significant experience as a researcher and a clinician that will be critical to Oculis’ expansion into neuro-ophthalmology and beyond, especially given the significant advancement with Privosegtor (OCS-05) in acute optic neuritis. The appointment of Sebastian Wolf, M.D., Ph.D., a distinguished global retina and imaging expert, as Chief Medical Advisor, Ophthalmology, comes during a period of laser-focused quality execution by Oculis of the late-stage Phase 3 DIAMOND program in diabetic macular edema, ahead of topline results expected in Q2 2026 and subse...